RARE vs. SANA

Last updated Apr 2, 2026

Compare and contrast key facts about Ultragenyx Pharmaceutical Inc. (RARE) and Sana Biotechnology, Inc. (SANA).

Performance

RARE vs. SANA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ultragenyx Pharmaceutical Inc. (RARE) and Sana Biotechnology, Inc. (SANA). The values are adjusted to include any dividend payments, if applicable.

RARE vs. SANA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
RARE Ultragenyx Pharmaceutical Inc.	-6.87%	-45.33%	-12.02%	3.22%	-44.90%	-45.75%
SANA Sana Biotechnology, Inc.	-25.06%	149.69%	-60.05%	3.29%	-74.48%	-55.90%

Fundamentals

Market Cap RARE : $2.14B SANA : $772.36M
EPS RARE : -$5.79 SANA : -$0.97
PB Ratio RARE : 132.43 SANA : 4.80
Total Revenue (TTM) RARE : $672.72M SANA : $0.00
Gross Profit (TTM) RARE : $564.07M SANA : $0.00
EBITDA (TTM) RARE : -$488.57M SANA : -$250.32M

Returns By Period

In the year-to-date period, RARE achieves a -6.87% return, which is significantly higher than SANA's -25.06% return.

RARE

• 1D: 2.24%
• 1M: -6.95%
• YTD: -6.87%
• 6M: -28.58%
• 1Y: -36.70%
• 3Y*: -18.86%
• 5Y*: -28.32%
• 10Y*: -10.71%

SANA

• 1D: 5.90%
• 1M: -26.51%
• YTD: -25.06%
• 6M: -17.57%
• 1Y: 103.33%
• 3Y*: -2.29%
• 5Y*: -37.51%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

RARE vs. SANA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RARE

RARE Risk / Return Rank: 18
RARE Sharpe Ratio Rank: 18
RARE Sortino Ratio Rank: 23
RARE Omega Ratio Rank: 21
RARE Calmar Ratio Rank: 14
RARE Martin Ratio Rank: 12

SANA

SANA Risk / Return Rank: 72
SANA Sharpe Ratio Rank: 73
SANA Sortino Ratio Rank: 77
SANA Omega Ratio Rank: 72
SANA Calmar Ratio Rank: 70
SANA Martin Ratio Rank: 67

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RARE vs. SANA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ultragenyx Pharmaceutical Inc. (RARE) and Sana Biotechnology, Inc. (SANA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RARE	SANA	Difference
Sharpe ratio Return per unit of total volatility	-0.51	0.98	-1.50
Sortino ratio Return per unit of downside risk	-0.27	1.97	-2.24
Omega ratio Gain probability vs. loss probability	0.95	1.24	-0.29
Calmar ratio Return relative to maximum drawdown	-0.74	1.49	-2.23
Martin ratio Return relative to average drawdown	-1.39	3.07	-4.46
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RARE vs. SANA - Sharpe Ratio Comparison

The current RARE Sharpe Ratio is -0.51, which is lower than the SANA Sharpe Ratio of 0.98. The chart below compares the historical Sharpe Ratios of RARE and SANA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	RARE	SANA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.51	0.98	-1.50
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.53	-0.32	-0.21
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.19	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.09	-0.32	+0.23

Correlation

The correlation between RARE and SANA is 0.41, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

RARE vs. SANA - Dividend Comparison

Neither RARE nor SANA has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

RARE vs. SANA - Drawdown Comparison

The maximum RARE drawdown since its inception was -89.57%, smaller than the maximum SANA drawdown of -96.92%. Use the drawdown chart below to compare losses from any high point for RARE and SANA.

Drawdown Indicators

	RARE	SANA	Difference
Max Drawdown Largest peak-to-trough decline	-89.57%	-96.92%	+7.35%
Max Drawdown (1Y) Largest decline over 1 year	-55.36%	-54.73%	-0.63%
Max Drawdown (5Y) Largest decline over 5 years	-84.01%	-95.83%	+11.82%
Max Drawdown (10Y) Largest decline over 10 years	-89.57%	—	—
Current Drawdown Current decline from peak	-87.92%	-92.99%	+5.07%
Average Drawdown Average peak-to-trough decline	-54.29%	-81.10%	+26.81%
Ulcer Index Depth and duration of drawdowns from previous peaks	29.35%	26.57%	+2.78%

Volatility

RARE vs. SANA - Volatility Comparison

The current volatility for Ultragenyx Pharmaceutical Inc. (RARE) is 18.41%, while Sana Biotechnology, Inc. (SANA) has a volatility of 24.65%. This indicates that RARE experiences smaller price fluctuations and is considered to be less risky than SANA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RARE	SANA	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.41%	24.65%	-6.24%
Volatility (6M) Calculated over the trailing 6-month period	67.91%	67.60%	+0.31%
Volatility (1Y) Calculated over the trailing 1-year period	71.88%	106.47%	-34.59%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	54.12%	118.85%	-64.73%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	55.60%	118.78%	-63.18%

Financials